Toxicity Management of Systemic Kidney Cancer Therapies

被引：0
作者：
Qin, Qian [1 ,2 ]
Nein, Ellen [1 ]
Flaten, Andrea [1 ,2 ]
Zhang, Tian [1 ,2 ,3 ]
机构：
[1] UT Southwestern Med Ctr, Dept Internal Med, Div Hematol Oncol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
[2] Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[3] Univ Texas Southwestern Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2023年 / 37卷 / 05期
关键词：
Renal cell carcinoma; Adverse events; Toxicity management; Immune-related adverse events; RENAL-CELL CARCINOMA; ANGIOGENESIS INHIBITORS; PLUS AXITINIB; OPEN-LABEL; PHASE-I; HYPERTENSION; SUNITINIB; SORAFENIB; TRIAL; CABOZANTINIB;
D O I：
10.1016/j.hoc.2023.05.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：993 / 1003
页数：11
相关论文
共 52 条
  • [1] Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis
    Abdel-Qadir, Husam
    Ethier, Josee-Lyne
    Lee, Douglas S.
    Thavendiranathan, Paaladinesh
    Amir, Eitan
    [J]. CANCER TREATMENT REVIEWS, 2017, 53 : 120 - 127
  • [2] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    Albiges, Laurence
    Tannir, Nizar M.
    Burotto, Mauricio
    McDermott, David
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    George, Saby
    Kollmannsberger, Christian K.
    Gurney, Howard
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Castellano, Daniel
    Rini, Brian, I
    Choueiri, Toni K.
    Saggi, Shruti Shally
    McHenry, M. Brent
    Motzer, Robert J.
    [J]. ESMO OPEN, 2020, 5 (06)
  • [3] [Anonymous], Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guide lines
  • [4] Nivolumab plus cabozantinib (N plus C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
    Apolo, Andrea B.
    Powles, Thomas
    Burotto, Mauricio
    Bourlon, Maria Teresa
    Hsieh, James J.
    Basso, Umberto
    Shah, Amishi Yogesh
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos H.
    Gurney, Howard
    Kessler, Elizabeth R.
    Retz, Margitta
    George, Saby
    Escudier, Bernard
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
    Apolo, Andrea B.
    Nadal, Rosa
    Girardi, Daniel M.
    Niglio, Scot A.
    Ley, Lisa
    Cordes, Lisa M.
    Steinberg, Seth M.
    Sierra Ortiz, Olena
    Cadena, Jacqueline
    Diaz, Carlos
    Mallek, Marissa
    Davarpanah, Nicole N.
    Costello, Rene
    Trepel, Jane B.
    Lee, Min-Jung
    Merino, Maria J.
    Bagheri, Mohammad Hadi
    Monk, Paul
    Figg, William D.
    Gulley, James L.
    Agarwal, Piyush K.
    Valera, Vladimir
    Chalfin, Heather J.
    Jones, Jennifer
    Streicher, Howard
    Wright, John J.
    Ning, Yangmin M.
    Parnes, Howard L.
    Dahut, William L.
    Bottaro, Donald P.
    Lara, Primo N., Jr.
    Saraiya, Biren
    Pal, Sumanta K.
    Stein, Mark N.
    Mortazavi, Amir
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3672 - +
  • [6] Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
    Barroso-Sousa, Romualdo
    Barry, William T.
    Garrido-Castro, Ana C.
    Hodi, F. Stephen
    Min, Le
    Krop, Ian E.
    Tolaney, Sara M.
    [J]. JAMA ONCOLOGY, 2018, 4 (02) : 173 - 182
  • [7] Marked and rapid effects of pharmacological HIF-2α antagonism on hypoxic ventilatory control
    Cheng, Xiaotong
    Prange-Barczynska, Maria
    Fielding, James W.
    Zhang, Minghao
    Burrell, Alana L.
    Lima, Joanna Dcc
    Eckardt, Luise
    La Argles, Isobel
    Pugh, Christopher W.
    Buckler, Keith J.
    Robbins, Peter A.
    Hodson, Emma J.
    Bruick, Richard K.
    Collinson, Lucy M.
    Rastinejad, Fraydoon
    Bishop, Tammie
    Ratcliffe, Peter J.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (05) : 2237 - 2251
  • [8] Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
    Choueiri, T. K.
    Eto, M.
    Kopyltsov, E.
    Rha, S. Y.
    Porta, C. G.
    Motzer, R.
    Gruenwald, V.
    Hutson, T. E.
    Mendez-Vidal, M. J.
    Hong, S-H.
    Winquist, E.
    Goh, J. C. H.
    Maroto, P.
    Buchler, T.
    Takagi, T.
    Rodriguez-Lopez, K.
    Xing, D.
    Smith, A. D.
    Powles, T.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S683 - S685
  • [9] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Escudier, B.
    Bourlon, M. T.
    Zurawski, B.
    Juarez, V. M. Oyervides
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Goh, J. C.
    Barrios, C.
    Richardet, M.
    Porta, C.
    Kowalyszyn, R.
    Feregrino, J. P.
    Zolnierek, J.
    Pook, D.
    Kessler, E. R.
    Tomita, Y.
    Mizuno, R.
    Bedke, J.
    Zhang, J.
    Maurer, M. A.
    Simsek, B.
    Ejzykowicz, F.
    Schwab, G. M.
    Apolo, A. B.
    Motzer, R. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) : 829 - 841
  • [10] Choueiri TK, 2020, ANN ONCOL, V31, P1030, DOI [10.1016/j.annoc.2020.04.010, 10.1016/j.annonc.2020.04.010]
123456